Stocktoria

ARTIVION, INC. AORT

NYSE · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1993-02-12 · LEI

ARTIVION, INC. (AORT) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.30% (safety: no dividend). FY2025 revenue was $441.3M at a 2.2% net margin.

Chart by TradingView
67/100
Stocktoria Quality Score · grade B
7/9
Piotroski F — financial health
3.05
Altman Z″ — distress risk · safe
1%
Dividend yield 5y avg · no dividend
-2.44
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 4 4 6 3 4 2 6 4 7 2016201720182019202020212022202320242025
Altman Z″
5.29 2.75 2.95 2.86 2.30 2.40 2.30 2.28 2.50 3.05 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$28.64 as of 2026-08-01 · -34.8% 1y
$22.19$46.6652-wk

Beneish M-score: -2.44 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$1.1B
P / E117.3×
Net margin 5y avg-4.2%
Beta1.26
Employees1,800

Analyst price target

$42.00 +46.6% vs last
consensus: strong buy · 8 analysts
target range $36.00 – $48.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$910,739 on the open market · 2 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 90%
Net marginstronger than 59%
Return on equitystronger than 61%
Revenue growthstronger than 71%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 7/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.29
Retained earnings / assets-0.058
EBIT / assets0.038
Equity / liabilities1.027

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
AORTARTIVION, INC.7/93.05117.3+13.6%
ARAYACCURAY INC6/9-1.53+2.7%
MDXGMIMEDX GROUP, INC.5/98.0612+20%
GKOSGLAUKOS Corp2/90.74+32.3%
ATRCAtriCure, Inc.7/93.44+14.9%
TCMDTACTILE SYSTEMS TECHNOLOGY INC7/98.5235.8+12.5%
ANGOANGIODYNAMICS INC5/9-1.82+9.5%

All Manufacturing companies →

About ARTIVION, INC.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

FAQ

Is AORT financially healthy?

ARTIVION, INC.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does AORT pay a dividend, and is it safe?

Yes. ARTIVION, INC. pays a dividend yielding about 0.30% with a None payout ratio, rated “no dividend” for safety.

How profitable is AORT?

In FY2025, ARTIVION, INC. had a net margin of 2.2% and a return on equity of 2.2%.

Is AORT overvalued or undervalued?

ARTIVION, INC. trades at about 136.4× trailing earnings — above its 10-year norm (10-year range 18.9×–594.8×, median 59.4×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for AORT?

The average Wall-Street price target for ARTIVION, INC. is $42.00, about 46.6% above the recent price, from 8 analysts (consensus: strong buy).

Is AORT a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on ARTIVION, INC.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 117.3×, a dividend yield of 0.30%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.